Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
ByteDance Plans Massive AI Investment in 2026 to Close Gap With U.S. Tech Giants 
California DMV Proposes New Safety Rules for Autonomous Vehicles After Waymo Incidents 
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement 
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccines Portfolio 
Saks Global Weighs Chapter 11 Bankruptcy Amid Debt Pressures and Luxury Retail Slowdown 
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing 
BP Nears $10 Billion Castrol Stake Sale to Stonepeak 
Texas App Store Age Verification Law Blocked by Federal Judge in First Amendment Ruling 
Boeing Wins $2.04B U.S. Air Force Contract for B-52 Engine Replacement Program 
Warner Bros. Discovery Shares Slide Amid Report of Potential Paramount Skydance Lawsuit 
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue 
Waymo Plans Safety and Emergency Response Upgrades After San Francisco Robotaxi Disruptions 
Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal 
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio 
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage 
PARSIPPANY, N.J., Nov. 10, 2016 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that senior leadership is scheduled to present an overview of the company at the following investor conferences in November:
- Jefferies 2016 London Healthcare Conference at 2:00 p.m. GMT (9:00 a.m. ET) in London on Thursday, November 17, 2016.
- 28th Annual Piper Jaffray Healthcare Conference at 11:00 a.m. ET in New York on Tuesday, November 29, 2016.
Live audio webcasts of the Pacira presentations can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. Replays of the webcasts will be archived on the Pacira website for two weeks following the respective presentation dates.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension), indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia, was commercially launched in the United States in April 2012. EXPAREL and two other products have successfully utilized DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. Additional information about Pacira is available at www.pacira.com.
Company Contact: Pacira Pharmaceuticals, Inc. Jessica Cho, (973) 254-3574 [email protected]
